- Home
- EBS
as 07-26-2024 4:00pm EST
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company operates across three different segments, namely Commercial, Products, and Services. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.
| Founded: | 1998 | Country: | United States |
| Employees: | N/A | City: | GAITHERSBURG |
| Market Cap: | 249.4M | IPO Year: | 2006 |
| Target Price: | $8.00 | AVG Volume (30 days): | 3.1M |
| Analyst Decision: | Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -10.94 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.42 - $14.61 | Next Earning Date: | 08-06-2024 |
| Revenue: | $1,185,400,000 | Revenue Growth: | 21.32% |
| Revenue Growth (this year): | -0.6% | Revenue Growth (next year): | 10.16% |
Stock Insider Trading Activity of Emergent Biosolutions Inc. (EBS)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Zoon Kathryn C | EBS | Director | Jun 4 '24 | Sell | $6.11 | 10,000 | $61,100.00 | 54,482 | SEC Form 4 |
| Zoon Kathryn C | EBS | Director | May 29 '24 | Sell | $4.61 | 1,830 | $8,436.30 | 64,482 | SEC Form 4 |
Latest Emergent Biosolutions Inc. News
EBS Breaking Stock News: Dive into EBS Ticker-Specific Updates for Smart Investing
MarketWatch
a day ago
The stock market’s cruel summer is about to get much worse
GlobeNewswire
3 days ago
Emergent BioSolutions Launches Opioid Emergency Preparedness ‘Lay, Spray, Stay’ Public Education Campaign Starring Pro Football Hall of Famer Emmitt Smith
GlobeNewswire
3 days ago
Emergent BioSolutions to Release Second Quarter 2024 Financial Results & Conduct Conference Call on August 6, 2024
MT Newswires
4 days ago
Emergent Biosolutions Says Narcan Nasal Spray's Shelf Life Extended to Four Years
GlobeNewswire
4 days ago
Emergent BioSolutions Announces Shelf-Life Extension for NARCAN® Nasal Spray in Canada
GlobeNewswire
18 days ago
Emergent BioSolutions Continues to Drive Improved Financial Position as Part of Multi-Year Transformation Plan
MT Newswires
18 days ago
Emergent Biosolutions, Johnson & Johnson Settle Dispute Over COVID-19 Vaccine Manufacturing
Pharmaceutical Technology
23 days ago
Emergent scores US medical countermeasure contracts worth over $250m
Compare EBS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "EBS Emergent Biosolutions Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.